Journal
BIOSCIENCE REPORTS
Volume 31, Issue 1, Pages 1-15Publisher
PORTLAND PRESS LTD
DOI: 10.1042/BSR20100077
Keywords
cancer therapy; eukaryotic initiation factor (eIF); prognosis; translational control; tumorigenesis
Categories
Funding
- National Institutes of Health [R01 CA94961]
- Showalter Research Trust Fund
- National High-Tech R&D Program of China [2009AA022704]
- National Natural Science Foundation of China [30873089]
- China Scholarship Council
- Graduate Degree Thesis Innovation Foundation of Central South University [2009ybfz09]
- Hunan Province Innovation Foundation [CX2009B060]
Ask authors/readers for more resources
Translational control is one of primary regulation mechanisms of gene expression. Eukaryotic translational control mainly occurs at the initiation step, the speed-limiting step, which involves more than ten translation initiation factors [eIFs (eukaryotic initiation factors)]. Changing the level or function of these eIFs results in abnormal translation of specific mRNAs and consequently abnormal growth of cells that leads to human diseases, including cancer. Accumulating evidence from recent studies showed that the expression of many eIFs was associated with malignant transformation, cancer prognosis, as well as gene expression regulation. In the present paper, we perform a critical review of recent advances in understanding the role and mechanism of eIF action in translational control and cancer as well as the possibility of targeting eIFs for therapeutic development.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available